Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy-early promise but more data needed

Aliment Pharmacol Ther. 2019 Mar;49(6):816-817. doi: 10.1111/apt.15081.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Drug Monitoring*
  • Gastrointestinal Agents
  • Humans
  • Inflammatory Bowel Diseases*
  • Infliximab
  • Patients
  • Recurrence

Substances

  • Gastrointestinal Agents
  • Infliximab